Characterization of a recombinant vaccinia virus expressing human melanoma-associated antigen p97.

1988 ◽  
Vol 62 (1) ◽  
pp. 176-180 ◽  
Author(s):  
S L Hu ◽  
G D Plowman ◽  
P Sridhar ◽  
U S Stevenson ◽  
J P Brown ◽  
...  
Keyword(s):  
Vaccinia Virus ◽  
Recombinant Vaccinia Virus ◽  
Human Melanoma ◽  
Recombinant Vaccinia

Cloning and characterization of a surface antigen of Eimeria tenella merozoites and expression using a recombinant vaccinia virus

1993 ◽  
Vol 61 (2) ◽  
pp. 179-187 ◽  
Author(s):  
Mary-Helen Binger ◽  
Denis Hug ◽  
Gilbert Weber ◽  
Eugene Schildknecht ◽  
Markus Hümbelin ◽  
...  
Keyword(s):  
Vaccinia Virus ◽  
Surface Antigen ◽  
Recombinant Vaccinia Virus ◽  
Eimeria Tenella ◽  
Recombinant Vaccinia

scholarly journals Development of Cell-Based Assays for In Vitro Characterization of Hepatitis C Virus NS3/4A Protease Inhibitors

2005 ◽  
Vol 49 (4) ◽  
pp. 1381-1390 ◽  
Author(s):  
Victoria Chung ◽  
Anthony R. Carroll ◽  
Norman M. Gray ◽  
Nigel R. Parry ◽  
Pia A. Thommes ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Vaccinia Virus ◽  
Protease Inhibitors ◽  
Expression System ◽  
Recombinant Vaccinia Virus ◽  
Enzyme Linked Immunosorbent Assay ◽  
Recombinant Vaccinia

ABSTRACT A recombinant vaccinia virus, expressing the NS3-to-NS5 region of the N clone of hepatitis C virus (HCV), was generated and utilized both in a gel-based assay and in an enzyme-linked immunosorbent assay (ELISA) to evaluate the pyrrolidine-5,5-trans-lactams, a series of inhibitors of the HCV NS3/4A protease. The absolute levels of processed, mature HCV nonstructural proteins in this system were found to decrease in the presence of the trans-lactams. Monitoring of this reduction enabled end points and 50% inhibitory concentrations to be calculated in order to rank the active compounds according to potency. These compounds had no effect on the transcription or translation of the NS3-5 polyprotein at concentrations shown to inhibit NS3/4A protease, and they were shown to be specific inhibitors of this protease. The ELISA, originally developed using the vaccinia virus expression system, was modified to utilize Huh-7 cells containing an HCV replicon. Results with this assay correlated well with those obtained with the recombinant vaccinia virus assays. These results demonstrate the utility of these assays for the characterization of NS3/4A protease inhibitors. In addition, inhibitors of other viral targets, such as polymerase and helicase, can be evaluated in the context of the replicon ELISA.

scholarly journals Expression and characterization of glycoprotein gp35 of hepatitis C virus using recombinant vaccinia virus

1992 ◽  
Vol 73 (9) ◽  
pp. 2313-2318 ◽  
Author(s):  
M. Kohara ◽  
K. Tsukiyama-Kohara ◽  
N. Maki ◽  
K. Asano ◽  
K. Yamaguchi ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Vaccinia Virus ◽  
Recombinant Vaccinia Virus ◽  
Recombinant Vaccinia

scholarly journals Expression and characterization of bovine lactoperoxidase by recombinant vaccinia virus

2008 ◽  
Vol 58 (3) ◽  
pp. 127-133
Author(s):  
Tetsuya Tanaka ◽  
Xuenan Xuan ◽  
Asato Kojima ◽  
Ikuo Igarashi ◽  
Kozo Fujisaki ◽  
...  
Keyword(s):  
Vaccinia Virus ◽  
Recombinant Vaccinia Virus ◽  
Recombinant Vaccinia

scholarly journals Recombinant vaccinia virus vaccine against the human melanoma antigen p97 for use in immunotherapy.

1988 ◽  
Vol 85 (4) ◽  
pp. 1052-1056 ◽  
Author(s):  
C. D. Estin ◽  
U. S. Stevenson ◽  
G. D. Plowman ◽  
S. L. Hu ◽  
P. Sridhar ◽  
...  
Keyword(s):  
Vaccinia Virus ◽  
Virus Vaccine ◽  
Recombinant Vaccinia Virus ◽  
Human Melanoma ◽  
Recombinant Vaccinia ◽  
Melanoma Antigen

Immunological and virological characterization of improved construction of recombinant vaccinia virus expressing rinderpest virus hemagglutinin

1991 ◽  
Vol 116 (1-4) ◽  
pp. 81-90 ◽  
Author(s):  
K. Asano ◽  
K. Tsukiyama ◽  
S. Shibata ◽  
K. Yamaguchi ◽  
T. Momoki ◽  
...  
Keyword(s):  
Vaccinia Virus ◽  
Recombinant Vaccinia Virus ◽  
Rinderpest Virus ◽  
Recombinant Vaccinia

scholarly journals Construction and Characterization of a Triple-Recombinant Vaccinia Virus Encoding B7-1, Interleukin 12, and a Model Tumor Antigen

1998 ◽  
Vol 90 (24) ◽  
pp. 1881-1887 ◽  
Author(s):  
M. W. Carroll ◽  
B. Moss ◽  
W. W. Overwijk ◽  
D. R. Surman ◽  
N. P. Restifo ◽  
...  
Keyword(s):  
Vaccinia Virus ◽  
Tumor Antigen ◽  
Recombinant Vaccinia Virus ◽  
Interleukin 12 ◽  
Recombinant Vaccinia ◽  
Model Tumor
Sign in / Sign up

Export Citation Format

Share Document